Mer­ck, Roche and Bris­tol My­ers nab 4 of 6 pos­i­tive ODAC votes for ‘dan­gling’ ac­cel­er­at­ed ap­provals

What looked at the out­set like a prime op­por­tu­ni­ty for the FDA to cri­tique in­dus­try over failed con­fir­ma­to­ry tri­als for lag­ging ac­cel­er­at­ed ap­provals end­ed up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER